Bristol Meyers Squibb
Dec 05, 2019
Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS. Reblozyl ((luspatercept-aamt) has recently been approved by the regulatory authority to cure a rare type of blood disorder, Beta-thalassemi...
Read More...
Apr 23, 2019
Notizia
Keytruda wins FDA nod for treating Kidney Cancer Merck’s Keytruda has recently got the U.S. FDA approval to be administered for Kidney Cancer. The drug Keytruda was approved in combination with Pfizer’s Inlyta for the treatment of advanced renal carcinoma. This therapy could prove to be serious for competition B...
Read More...
Aug 24, 2016
Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer
Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
